
Biogen terminates gosuranemab in progressive surpanuclear palsy following Phase 2 failure
pharmafile | December 16, 2019 | News story | Research and Development, Sales and Marketing | Biogen, pharma, trial failure
Biogen has revealed its intention to shut down further development of gosuranemab after results of a Phase 2 study showed that the drug failed to meet its primary endpoint in the treatment of progressive supranuclear palsy (PSP).
The findings of the study showed that gosuranemab did not offer “statistically significant” clinical benefit in the disease as indicated on the PSP rating scale (PSPRS) after 52 weeks of treatment. The company also noted that the study failed to show efficacy on the key clinical secondary endpoints.
It was noted, however, that safety results for the therapy were consistent with previous findings, with data to be presented at a future event.
“We are disappointed with the efficacy results of the Phase 2 PASSPORT study,” said Dr Alfred Sandrock Jr, Executive Vice President, Research and Development and Chief Medical Officer at Biogen. “We remain unwavering in our commitment to advancing therapies that have the potential to address the significant unmet medical needs of people with neurodegenerative diseases who are faced with limited to no treatment options.”
Despite these trials terminations, Biogen confirmed it will continue evaluating the drug in the ongoing Phase 2 trial for the treatment of mild cognitive impairment due to Alzheimer’s disease.
Matt Fellows
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

Biogen’s high-dose Spinraza regimen receives European Commission approval for spinal muscular atrophy
Biogen’s Spinraza (nusinersen) has received approval from the European Commission (EC) as a new high-dose …






